FragMAX, a project run in collaboration between LP3, MAXIV, Astra Zeneca and SARomics Biostructures, has been awarded funding from the Swedish Research Council. The project aims to establish a fragment based screening facility, enabling scientists and small companies to screen low molecular weight fragments for binding to target proteins using X-ray crystallography.